Skip to main content

Evidence-Based Supplement Research

Evidence-Based Supplement Research

Bifidobacterium breve BBr60 and Increased Intestinal GLP-1 Levels

Doses used in studies

CFU/day: 10 billion (median 10 billion, IQR 10 billion–10 billion) — 1 study

Time to effect

Median: 2.8 months · IQR 2.8 months–2.8 months · Range 2.8 months–2.8 months — Reported in 1 of 1 study

1 of 1 paper

Bifidobacterium Breve BBr60 Improves Obesity Via the Gut Microbiota-Short-Chain Fatty Acid-IL-27/GLP-1 Axis: Evidence from a Randomized, Double-Blind, Placebo-Controlled Trial.
- 2025-12-27
- RCT · n = 75
- Probiotics and antimicrobial proteins 18(4)
- - Dejiao Gao
  - Yao Dong
  - Zhumin Jia
  - Chenying Bian
  - Jianguo Zhu
  - Ying Wu
  - Shuguang Fang
  - Shaobin Gu
- PubMed: 41455007
- DOI: 10.1007/s12602-025-10885-9
11 Insights on
- Increased Intestinal GLP-1 Levels
- High evidence
- Rigorous Journal
- Clinical
Glucagon-Like Peptide-1 (GLP-1) ... were all significantly elevated (p < 0.05)
Effect
Beneficial
Effect size
Small
Significant
Yes
Dose
10 billion CFU daily